{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_6555545_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"095-447-724-632-546","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8676,"type":"PATENT","title":"New York University Patent Portforlio ","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5145,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2015-11-12T00:15:20Z","updated":"2015-11-23T01:36:42Z","lastEventDate":"2015-11-23T01:36:42Z"},{"id":8877,"type":"PATENT","title":"New York Univ Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15466,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8211,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners seperately = \"New York Univ\", \"New York University NOT \"state\" NOT \"city\" \", \"Univ New York\", \"NYU\".
Search Applicants and Owners seperately = \"New York Univ\", \"New York University NOT \"state\" NOT \"city\" \", \"Univ New York\", \"NYU\".
1,3-dipropyl phenylxanthine and 4-{2-[7-amino-2-(2-furyl)[1,2,4]-triazolo[2,3-a][1,3,5]-triazin-5-ylamino]ethyl}phenol (ZM 241385), 8-styryl derivatives of 1,3-7-alkylxanthines of the following formula:
wherein
R 1 and R 3 are methyl, ethyl, propyl, or allyl;
R 7 is H, methyl, or C 1 -C 8 alkyl;
R∝ is hydrogen; and compounds of the following formula:
wherein Y=m-Br or p-SO 3 H."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating hepatic fibrosis or cirrhosis or fatty acids comprising administering to a subject in need thereof an effective amount of at least one adenosine A 2A receptor antagonist or at least one adenosine uptake promotor."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 3 wherein the adenosine A 2A receptor antagonist is selected from the group consisting of wherein
R 1 and R 3 are methyl, ethyl, propyl, or allyl;
R 7 is H, methyl, or C 1 -C 8 alkyl;
R is hydrogen; and compounds of the following formula:
wherein Y=m-Br or p-SO 3 H."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 4 wherein the adenosine A 2A receptor antagonist is selected from the group consisting of 8-(3-chlorostyryl) caffeine and 4-{2-[7-amino-2-(2-furyl)(1,2,4)triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl}phenol, also known as ZM 241385."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["A method for preventing development of hepatic fibrosis, cirrhosis, or fatty liver comprising administering to a subject in need thereof an effective amount of at least one agent which inhibits stimulation of the adenosine A 2A receptor."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating hepatic fibrosis or cirrhosis or fatty liver comparing administering to a subject in need thereof an effective amount of at least one agent which inhibits stimulation of the A 2A receptor."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A method for preventing development of fibrosis comprising administering to a subject in need thereof an effective amount of at least one adenosine A 2A receptor antagonist."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 8 wherein the adenosine A 2A receptor antagonist is selected from the group consisting of adenosine, 2-phenylaminoadenosine; 2-p-carboxyethylphenylamino-5′-N-ethylcarboxaminoadenosine; 5-N-ethylcarboxamidoadenosine; 5′-N-cyclopropyladenosine; 5′-N-methylcarboxamidoadenosine; 8-(3-chlorostyryl) caffeine; PD-125944, 1,3-dipropyl phenylxanthine; 4-{2-[7-amino-2-(2-furyl)(1,2,4)-triazolo[2,3-a][1,3,5]-triazin-5-ylamino]ethyl}phenol; 8-styryl derivatives of 1,3,7-alkylxanthines of the formula: wherein
R 1 and R 3 are methyl, ethyl, propyl, or allyl;
R 7 is H, methyl, or C 1 -C 8 alkyl;
R∝ is hydrogen; and compounds of the formula:
wherein Y is m-Br or p-SO 3 H."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating fibrosis comprising administering to a subject in need thereof an effective amount of at least one adenosine A 2A receptor antagonist or at least one adenosine uptake promoter."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 10 wherein the adenosine receptor antagonist is selected from the group consisting of wherein
R 1 and R 3 are methyl, ethyl, propyl, or allyl;
R 7 is H, methyl, or C 1 -C 8 alkyl;
R∝ is hydrogen; and compounds of the following formula:wherein Y=m-Br or p-SO 3 H."],"number":11,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}